253 related articles for article (PubMed ID: 29199679)
21. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.
Lantuejoul S; Rouquette I; Blons H; Le Stang N; Ilie M; Begueret H; Grégoire V; Hofman P; Gros A; Garcia S; Monhoven N; Devouassoux-Shisheboran M; Mansuet-Lupo A; Thivolet F; Antoine M; Vignaud JM; Penault-Llorca F; Galateau-Sallé F; McLeer-Florin A
Eur Respir J; 2015 Jul; 46(1):207-18. PubMed ID: 25929957
[TBL] [Abstract][Full Text] [Related]
22. A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis.
Trejo Bittar HE; Luvison A; Miller C; Dacic S
Histopathology; 2017 Aug; 71(2):269-277. PubMed ID: 28316074
[TBL] [Abstract][Full Text] [Related]
23. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer.
Cutz JC; Craddock KJ; Torlakovic E; Brandao G; Carter RF; Bigras G; Deschenes J; Izevbaye I; Xu Z; Greer W; Yatabe Y; Ionescu D; Karsan A; Jung S; Fraser RS; Blumenkrantz M; Lavoie J; Fortin F; Bojarski A; Côté GB; van den Berghe JA; Rashid-Kolvear F; Trotter M; Sekhon HS; Albadine R; Tran-Thanh D; Gorska I; Knoll JH; Xu J; Blencowe B; Iafrate AJ; Hwang DM; Pintilie M; Gaspo R; Couture C; Tsao MS
J Thorac Oncol; 2014 Sep; 9(9):1255-63. PubMed ID: 25122422
[TBL] [Abstract][Full Text] [Related]
24. Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement.
Shan L; Lian F; Guo L; Yang X; Ying J; Lin D
Diagn Pathol; 2014 Jan; 9():3. PubMed ID: 24422905
[TBL] [Abstract][Full Text] [Related]
25. Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung.
Schildhaus HU; Deml KF; Schmitz K; Meiboom M; Binot E; Hauke S; Merkelbach-Bruse S; Büttner R
Mod Pathol; 2013 Nov; 26(11):1468-77. PubMed ID: 23743932
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S
PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725
[TBL] [Abstract][Full Text] [Related]
28. [ALK protein expression and gene fusion in bronchoscopic specimens of lung adenocarcinoma].
Liang X; Wang M; Zhang J; Luo Y; Zhang S; Wu S; Liu Y; Zeng X
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):501-4. PubMed ID: 25327654
[TBL] [Abstract][Full Text] [Related]
29. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
[TBL] [Abstract][Full Text] [Related]
30. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
Pekar-Zlotin M; Hirsch FR; Soussan-Gutman L; Ilouze M; Dvir A; Boyle T; Wynes M; Miller VA; Lipson D; Palmer GA; Ali SM; Dekel S; Brenner R; Bunn PA; Peled N
Oncologist; 2015 Mar; 20(3):316-22. PubMed ID: 25721120
[TBL] [Abstract][Full Text] [Related]
31. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.
Minca EC; Lanigan CP; Reynolds JP; Wang Z; Ma PC; Cicenia J; Almeida FA; Pennell NA; Tubbs RR
J Thorac Oncol; 2014 Apr; 9(4):464-8. PubMed ID: 24736067
[TBL] [Abstract][Full Text] [Related]
32. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
33. Anaplastic lymphoma kinase status in lung cancers: An immunohistochemistry and fluorescence
Murthy SS; Rajappa SJ; Gundimeda SD; Mallavarapu KM; Ayyagari S; Yalavarthi P; Fonseca D; Paliwal P; Nair H; Koppula V; Raju K; Rao ST
Indian J Cancer; 2017; 54(1):231-235. PubMed ID: 29199697
[TBL] [Abstract][Full Text] [Related]
34. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry.
Gruber K; Kohlhäufl M; Friedel G; Ott G; Kalla C
J Thorac Oncol; 2015 Apr; 10(4):713-6. PubMed ID: 25789835
[TBL] [Abstract][Full Text] [Related]
35. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.
Conde E; Suárez-Gauthier A; Benito A; Garrido P; García-Campelo R; Biscuola M; Paz-Ares L; Hardisson D; de Castro J; Camacho MC; Rodriguez-Abreu D; Abdulkader I; Ramirez J; Reguart N; Salido M; Pijuán L; Arriola E; Sanz J; Folgueras V; Villanueva N; Gómez-Román J; Hidalgo M; López-Ríos F
PLoS One; 2014; 9(9):e107200. PubMed ID: 25248157
[TBL] [Abstract][Full Text] [Related]
36. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
37. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
[TBL] [Abstract][Full Text] [Related]
38. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
[TBL] [Abstract][Full Text] [Related]
39. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples.
Abe H; Kawahara A; Azuma K; Taira T; Takase Y; Fukumitsu C; Murata K; Yamaguchi T; Akiba J; Ishii H; Okamoto I; Hoshino T; Takamori S; Kage M
J Thorac Oncol; 2015 May; 10(5):800-805. PubMed ID: 25898958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
